FIELD NOTE / THE PAIRING
CJC-1295 + ipamorelin
This page explains the CJC-1295 and ipamorelin pairing. They are two different peptides linked to growth-hormone release. The combination's name is familiar online, but the name does not establish its safety or support promises about training results.
NXT LVL may earn money when readers become Promise patients.
Promise lists CJC-1295 + ipamorelin. A licensed U.S. provider decides; not everyone qualifies. FDA still lists ipamorelin acetate in Category 2, its safety-concern group, for 503B only: larger compounding facilities. This is not a 503A Category 2 listing.
A licensed U.S. provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order and are not FDA-approved.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.
Two ingredients. Different signals.
Peptides are short chains of amino acids, the parts that make up proteins. CJC-1295 is a lab-made version of growth-hormone-releasing hormone, a signal sent from the brain to the pituitary gland beneath it. Ipamorelin uses the body's ghrelin signal pathway; ghrelin is a hormone associated with hunger.
Both are called growth-hormone secretagogues: substances that prompt a gland to release growth hormone. Neither is growth hormone itself. Saying they use different signals is a description of the molecules, not evidence that the pair gives a better result.
The form still matters.
CJC-1295 can mean a form with DAC, an added chemical part that attaches to a blood protein, or a form without it. DAC stands for drug affinity complex. FDA, the U.S. drug regulator, regards the forms as different ingredients. A blend label that only says CJC-1295 leaves an important question unanswered.
The CJC-1295 naming guide explains that distinction. Evidence for the form with DAC cannot simply be assigned to the other form.
What the human research leaves open.
The CJC-1295 human studies were small and mainly involved healthy adults. The published ipamorelin studies involved healthy men or people recovering from bowel surgery. These are not studies showing that the combined product meets training, recovery or body-composition goals.
FDA found no human study of CJC-1295 without DAC in its review. The evidence for a single ingredient also does not establish the safety of a combination.
A listing does not settle FDA status.
Neither CJC-1295 nor ipamorelin is an FDA-approved medicine. The combination is not FDA-approved either. Compounding means making a medicine to order. The FDA reviews find that both ingredients fail the current raw-ingredient requirements for routine pharmacy compounding.
On FDA's page current as of April 22, 2026, CJC-1295 appears among nominations that were withdrawn. Ipamorelin acetate, a chemical salt form, appears there too and also remains in Category 2, FDA's safety-concern group, for larger compounding facilities. Withdrawal is not clearance. FDA gives no individual withdrawal dates.
Promise lists these options for provider review. A licensed U.S. provider decides whether to prescribe. The listing does not change FDA status or the rules for the exact ingredient.
Questions that keep the details in view.
Which CJC-1295 form is named?
With DAC and without DAC are different ingredients. The full name matters.
Which evidence is for the pair?
Research on one component cannot stand in for a study of the combination.
What does the provider need to consider?
Health history, other medicines, the evidence for the intended use and the legal status all belong in the review. It can end without a prescription.
What FDA's safety concerns include.
CJC-1295
FDA reports serious reactions linked to CJC-1295, including a faster heart rate and flushing. It also notes dizziness and low blood pressure. FDA warns that the immune system may react to the peptide.
Ipamorelin
FDA is concerned that injected ipamorelin could trigger an immune reaction. No human study has checked its safety when injected under the skin.
In a study that gave ipamorelin into a vein, two patients died after complications of cancer surgery. FDA says it is unclear whether ipamorelin played a part.
Source notes
Put the next step in licensed hands.
A Promise visit starts a request for review. A licensed U.S. provider decides whether to prescribe. Not everyone qualifies, and no particular treatment is promised.
NXT LVL may earn money when readers become Promise patients.
Promise lists CJC-1295 + ipamorelin. A licensed U.S. provider decides; not everyone qualifies. FDA still lists ipamorelin acetate in Category 2, its safety-concern group, for 503B only: larger compounding facilities. This is not a 503A Category 2 listing.
A licensed U.S. provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order and are not FDA-approved.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.